Drug
Pumitamig clinical trials
Also written PM8002 and BNT327.
- studies test it
- 32
- open now
- 21
- in phase 3
- 9
- first study started
- 2021
Keep track of what changes. Save the pumitamig studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
32 studies that test it; most in 2025 (13)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 13 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 26
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 30 · Other 2
BioNTech SE (13) · Biotheus Inc. (11) · Bristol-Myers Squibb (5) · Shanghai Pulmonary Hospital, Shanghai, China (1) · M.D. Anderson Cancer Center (1) · DualityBio Inc. (1)
Often tested with
Tested in the same studies.
Paclitaxel (4) · Etoposide (2) · Beruzatatug pelitecan (2) · Carboplatin (1) · Topotecan (1) · Platinum (1) · Albumin-Bound Paclitaxel (1) · Anti-TIGIT/Anti-PVRIG Bispecific Antibody PM1009 (1)
Studies
Open first, then newest update. How each study uses pumitamig is read from its arms, and is right about nine times in ten.
Testing it · 32
- A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)RecruitingPhase 3Bristol-Myers SquibbNCT07361510Written as Pumitamig
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerRecruitingPhase 2/3Bristol-Myers SquibbNCT07221357Written as Pumitamig
- A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2BioNTech SENCT07111520Written as Pumitamig
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingPhase 3BioNTech SENCT07173751Written as Pumitamig
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingPhase 2/3BioNTech SENCT06712316Written as Pumitamig
- A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerRecruitingPhase 1/2BioNTech SENCT06827236Written as BNT327
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerRecruitingPhase 3BioNTech SENCT06712355Written as Pumitamig
- A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)Not yet recruitingPhase 2Bristol-Myers SquibbNCT07871214Written as Pumitamig
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsRecruitingPhase 1/2BioNTech SENCT07070232Written as Pumitamig
- A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)RecruitingPhase 3Bristol-Myers SquibbNCT07361497Written as Pumitamig
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)RecruitingPhase 2/3Bristol-Myers SquibbNCT07221149Written as Pumitamig
- Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung CancerRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07579221Written as Pumitamig
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerRecruitingPhase 1/2BioNTech SENCT06892548Written as BNT327
- A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerRecruitingPhase 1/2BioNTech SENCT07079631Written as Pumitamig
- A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid TumorsRecruitingPhase 1/2BioNTech SENCT07147348Written as Pumitamig
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsRecruitingPhase 2DualityBio Inc.NCT06953089Written as BNT327
- A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent GlioblastomaRecruitingPhase 2BioNTech SENCT07297212Written as Pumitamig
- Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line TreatmentRecruitingPhase 2BioNTech SENCT06841055Written as Pumitamig
- Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLCNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06837948Written as PM8002
- A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCNot yet recruitingPhase 1/2Biotheus Inc.NCT06584071Written as PM8002
See all 32 studies that test pumitamig →
Given in every arm · 14 — pumitamig is usual care beside what is tested
- A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)RecruitingPhase 1/2Bristol-Myers SquibbNCT07291076Written as Pumitamig
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)RecruitingPhase 1/2Bristol-Myers SquibbNCT07293351Written as Pumitamig
- A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Bristol-Myers SquibbNCT07680764Written as Pumitamig
- A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid TumorsRecruitingPhase 1/2Bristol-Myers SquibbNCT06697197Written as Pumitamig
- A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)RecruitingPhase 1/2Boehringer IngelheimNCT07843940Written as Pumitamig
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 2Bristol-Myers SquibbNCT07492680Written as Pumitamig
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingPhase 1/2Bristol-Myers SquibbNCT06618287Written as Pumitamig
- A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerRecruitingPhase 1/2Bristol-Myers SquibbNCT07325136Written as Pumitamig
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsRecruitingPhase 1/2Bristol-Myers SquibbNCT04895709Written as Pumitamig
- A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingPhase 1Bristol-Myers SquibbNCT07195682Written as Pumitamig
- A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid TumorsRecruitingPhase 1/2Bristol-Myers SquibbNCT07160725Written as Pumitamig
- A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic CancerRecruitingPhase 2BioNTech SENCT07255404Written as Pumitamig
- PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerRecruitingPhase 2Biotheus Inc.NCT07133750Written as PM8002
- First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid TumorsActive, not recruitingPhase 1/2DualityBio Inc.NCT05438329Written as BNT327
Codes
What other systems call pumitamig · ClinicalTrials.gg INT017680
- UNII (FDA) QEA2EG9S3EPUMITAMIGOne source FDA
- NCI Thesaurus C215265PumitamigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QEA2EG9S3E | PUMITAMIG | One source FDA |
| NCI Thesaurus | C215265 | Pumitamig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.